Office of the Vice-Principal (Research)

Office of the Vice-Principal (Research)
Office of the Vice-Principal (Research)

Harrington Scholar Award for Coronavirus

[This following information was sent by the Harrington Discovery Institute at University Hospitals, Cleveland, OH. See press release for more information.

Note: This is an accelerated grant program. The deadline to submit a proposal is April 30 and award recipients will be notified in May.

Request for Proposals can be downloaded from the Harrington Scholar Award for Coronavirus website here.

In addition to dedicated drug development support and project management, awardees will receive $150k guaranteed, with the potential to receive up to $1 million in charitable support.

Application submission:

  • The ‘Application Questions’ can be downloaded from the website. There is no need to log in to our grant system to submit the application as you have done in the past.
  • Completed application form should be emailed to Becca Koopman, our Program Coordinator, at rebecca.koopman@uhhospitals.org.

Projects being sought:

  • Novel therapies that can target Coronavirus and its co-morbidities, such as impact on lungs and heart.
  • Broad-spectrum anti-viral therapies, particularly targeting respiratory viruses.
  • Next generation vaccines that may target new Corona strains, multiple Corona viruses or more than one type of virus.
  • Emergency countermeasures/prophylaxis strategies for first responders and emergency medical personnel to be administered either once or short-term.

Emphasis of call:

  • Therapies that can enter clinical trials near-term (i.e., within 12 months) with HDI project management and financial support.
  • Breakthrough, differentiated technologies and discoveries.

Note that:

  • The HDI Therapeutics Development team will work with successful applicants to redirect promising therapies toward Coronavirus if applicable.
  • Funding from other sources (e.g. DoD, NIH, foundations) is welcomed but not required.
  • All therapeutic modalities will be considered.

Who is eligible?

  • Investigators from accredited academic medical centers, research institutions or universities in the U.S., Canada and the United Kingdom.
  • Lead investigators must have an M.D. or Ph.D. or equivalent.